Q4 earnings are the key if extension is granted.

If they get the extension, I’d expect the Q4 earnings to push it back into the 30’s or beyond if it isn’t already there by then.

TCE’s:
10/7 - 10,800 (4 ships)
10/20 - 10,800 (6 ships)
11/10 - 10,700 (6 ships)

3 of the ships (sun, moon, rainbow) have possible return dates of November at earliest (Sun had December at latest and Moon has November so we may see a new charter announcement soon with the Panamax index soaring).

Q3 earnings the TCE was barely above 8k. Barring any covid related delays we should see an average Q4 TCE 33% higher than Q3.

The real wildcard is what they are doing sitting on all that cash. 38m is totally unnecessary if you’re trying to get back over 1.00 - they should put 10-15m in to buy back half the public float or just erase all outstanding debt (20m or so). Buying more ships isn’t going to cut it when shareholders have already taken a bath to grow the fleet. If the goal is to avoid a R/S then realistically the only option is to do a stock buyback.

No news from shareholders meeting?

How is it possible that no news has leaked from the meeting in NYC yesterday? Around 1045am EST we saw a massive surge in volume (7m shares plus) that shot it from low 14’s to 17.

My guess (and hope) is that they told shareholders that they plan on getting the additional 180 day extension from Nasdaq to meet the bid price requirements. This would require the reverse split proposed to have been approved during the shareholders meeting first as Nasdaq needs to know how the company intends to cure the deficiency during the next 180 days.

There are only 18 business days left until the deadline and the bid price has to be above 1.00 for 10 straight of those days. So either Nasdaq is granting the extension soon or *gulp* CTRM will have to execute the reverse within a couple business days max.

Based on the action and volume we saw yesterday I am optimistic that they won’t execute a R/S. The only other possibility is that they use their massive cash reserves (38m per last earnings report) to buy back much of the public float but even that isn’t a guarantee to get it over 1.00 for 10 days. 15m would buy almost 94m shares at the current price of just below .16

Guess we’ll hear by tomm but there is no reason for them to execute a reverse split and further crush shareholder value when they have so much reserve cash and a potential for another 180 day extension on the table.

No human lung cell data, no human trials, just a grant application

It should be obvious by now that the ship for B for C has sailed. Now they dish out a PR saying they’re collaborating on a grant to study B as a broad spectrum antiviral. This is really the only hope for B - that it may get free money to study its application elsewhere. After all this time, and all the PR’s promising human lung cell data and to rapidly advance B into human trials, you’ve got Petri dish testing in monkey veto cells and a human kidney cell line. No lung data, no human trials. Just someone to help them fill a grant application out.

Oh, the researchers are going to publish their data after completion of in in vitro testing? No crap, that’s what researchers do. Here I’ll tell you exactly what it’ll say “While B did not show efficacy against SARS-cov-2 in human lung cells in vitro, it may potentially have applications elsewhere.” Only problem is the company is broke and “elsewhere” isn’t what the last dozen PR’s were promising.

I sold because I made the determination that the risk was very high that B didn’t pass muster at the RBLs after reading the list of PR’s over the last 2 months and all the data that was promised which we haven’t received and selling at .17 is better than .8 if word comes out that it failed. Could I be wrong? Sure.

I want everyone to make money and for a treatment for Covid to be approved. lI’ve been lurking on the board for a while especially after the possible Covid indications for B Came to light. I started making a few posts because I became frustrated with the PR’s as time went on (I also had a much higher stake at that point) . I’m just amazed that people think that anyone that doesn’t worship at the alter of B or voices very reasonable doubts About where it stands after these very fishy PR’s is cast as a fake, fraud, or shorting the stock.

There’s phase 2 vaccine trials going on right now and scores of potential therapeutics being used in live humans right now. The fact that B was never advanced into human trials as of the timing of this post leads me to believe that Leo is hiding data. When a PR promises data on lung cells and you get a random kidney cell Petri dish lab instead the alarm bells start going off. Good luck to all.

Liquidated the rest of my holdings.

Have had shares for several years with a few buys and sells especially with the covid seesaw we’ve been on.

Had a lot of emotional attachment to this stock and after profiting off the last PR made the mistake to rebuy once it hit .20 with the classic FOMO.

But, if you look at Infinity and a previous poster’s list of the PR’s since the B-covid saga began, you can clearly tell that B did not pass muster at the RBL - It’s been months now and there would be press releases about the Positive data and surely a partner, a buyout, or at least human trials going. The last few press releases end with Leo asking potential partners on studying B to email him. That’s the tell. If this drug was effective it would already be far into advanced testing stages and Leo wouldn’t need to beg for help.

We were promised data on B in human lung cells a long time ago and all we were given is some kidney data.

Will there be another PR soon from Leo that might pump the stock? Absolutely - probably this week. But I’ve had enough.

GLTA

Still using Monkey cells? Preincubated?? WARNING

[quote ] RBL??? calling the RBL?!? green monkey cells- been there and done that. Instead of getting the data we have waited 18 days for now we are given other data about green monkey kidney epithelial cells.
RBL testing on lung cell cultures are not mentioned at all, nothing. Why? [/quote]

A lot of warning signs in this PR. We were told it would be human lung cells not VERO cells / preincubation with 10uM is testing you’d do for vaccine-like properties, we want to know how B works on infected human lung cells as a treatment / they announced it will no longer be pursued as a vaccine despite testing its vaccine-like properties / is 10uM a safe dosage? and what route? We don’t know because it’s in-vitro / the PR ends with asking for email inquiries for partners and additional research, if this is showing so much promise why is there no partner yet? / again the phrase rapidly advance into human trials is used and has been used for the last 2 months and not only has that not happened we don’t even have any data on human lung cells in vitro.

Why no compassionate care designation to get some human trials going?

Hoping this PR gets the stock to finally get back into the .20’s and any positive news is good but there’s a lot of snake oil warning signs here.

Cmon IPIX!

Yes, I’m a long and I’ve averaged down multiple times.

I’m hoping B beats the odds but my God anytime someone tries to post a reality check they get swarmed.

3 scenarios for these in-vitro studies at the RBLs

1) B has no effect on covid during these in-vitro studies. IPIX is bankrupt and trades below a nickel, if that.
2) B has some mild positive effect on covid, but not enough to warrant further studies or attract interest from larger pharmaceutical companies. IPIX is bankrupt and trades between a nickel and a dime. A minuscule chance exists that another company acquires the rights to B for one of its original purposes based on data garnered from the RBL studies. B has experienced this scenario already with meeting its phase 2 goals for trials with OM but with not good enough results to attract funding for a phase 3 trial.
3) B has a statistically significant effect on covid and advances into human trials. IPIX is still bankrupt so a larger pharma company partners with IPIX for a majority control of revenue from B if it succeeds, or a few potential partners lie in wait for the human trial results, or someone just buys it outright. IPIX likely trades between .25 and 1.00.

If there is good news, the PR will most likely be released before 830am on that day (most covid-related companies seem to be putting them out around 7am or as early as possible). Bad news will come right at 930am or just after the bell.

It’s important to realize this stock is a lottery ticket and we’re all hoping for scenario 3. Scenario 2 and 1 are most likely (as they are with most clinical stage biooharma drugs - most fail) but scenario 3 means a promising drug for covid patients and $ for shareholders.

Nice Support At .14

Strong support for IPIX at .14 - a definite change over the last few weeks.

Where are the B compassionate care human trials?

Small companies like CAPR are launching into the stratosphere based off of small Sample human trials with drugs that are no further along the pipeline than B.

You would think some hospital in the USA or Europe would be trialing B like CAPR was able to get done.

The need for B is greatest right now and I don’t understand why it hasn’t gotten a compassionate care designation while it continues to go through RBL testing.

It was a compassionate use designation - but the results were good enough to basically guarantee an actual study.

Re: IPIX getting left behind

It’s my second post (I’ve been lurking for a long time but only made an account recently) and I’m long on IPIX but am very concerned as I continue to see other drugs from small companies being used in actual covid+ humans while we sit and wait.

Warning signs

1)The study identifying B as one of the few compounds out of 11000+ was published 4/12. The PR released this morning was on 4/20. This means that these results were likely out there in public or at least being used by Leo in his negotiations for 1-3 weeks. The fact that there are Still no deals is highly discouraging.

2) The next phase of B being studied at the RBL has not begun yet. Each day that goes by is critical as other drugs like Remdisivir may be approved and become the front line drug of choice. Given the urgency of this crisis one would think any potential promising drug would be moved along must faster as Large numbers of people continue to die.

3) The PR announcing discussions to advance B into human trials was 4/6. It is now 2 weeks later and nothing.

4) This statement from that same 4/6 PR “There can be no assurance that any trials for B will commence.”

5) IPIX market cap is 32M. That’s pocket change for Big Pharma if they’re looking to just buy it out for the rights to a potential game changing drug

6) Using the PR to solicit potential collaborations by saying please email us your inquiries?

I just don’t understand how a drug that defied incredible odds and is 1 of only 15 identified by the study out of 11,000+ as potentially being useful for The coronavirus has not gained incredible traction let alone its current status of next to zero traction.